GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Beneish M-Score

WVE (WAVE Life Sciences) Beneish M-Score : -4.14 (As of Dec. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.14 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for WAVE Life Sciences's Beneish M-Score or its related term are showing as below:

WVE' s Beneish M-Score Range Over the Past 10 Years
Min: -7.96   Med: -1.53   Max: 23.46
Current: -4.14

During the past 11 years, the highest Beneish M-Score of WAVE Life Sciences was 23.46. The lowest was -7.96. And the median was -1.53.


WAVE Life Sciences Beneish M-Score Historical Data

The historical data trend for WAVE Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Beneish M-Score Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.10 -3.03 -3.05 -6.42 23.46

WAVE Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.25 23.46 4.74 0.33 -4.14

Competitive Comparison of WAVE Life Sciences's Beneish M-Score

For the Biotechnology subindustry, WAVE Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Beneish M-Score falls into.



WAVE Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of WAVE Life Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 1+0.404 * 0.5728+0.892 * 0.6271+0.115 * 0.9024
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.7561+4.679 * -0.031896-0.327 * 0.8355
=-4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $0.00 Mil.
Revenue was -7.676 + 19.692 + 12.538 + 29.056 = $53.61 Mil.
Gross Profit was -7.676 + 19.692 + 12.538 + 29.056 = $53.61 Mil.
Total Current Assets was $324.52 Mil.
Total Assets was $358.50 Mil.
Property, Plant and Equipment(Net PPE) was $30.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.69 Mil.
Selling, General, & Admin. Expense(SGA) was $56.55 Mil.
Total Current Liabilities was $170.73 Mil.
Long-Term Debt & Capital Lease Obligation was $19.77 Mil.
Net Income was -61.78 + -32.923 + -31.558 + -16.256 = $-142.52 Mil.
Non Operating Income was 2.135 + 2.074 + 2.9 + 2.426 = $9.54 Mil.
Cash Flow from Operations was -46.478 + -27.468 + -33.432 + -33.239 = $-140.62 Mil.
Total Receivables was $7.00 Mil.
Revenue was 49.214 + 22.106 + 12.929 + 1.239 = $85.49 Mil.
Gross Profit was 49.214 + 22.106 + 12.929 + 1.239 = $85.49 Mil.
Total Current Assets was $158.57 Mil.
Total Assets was $199.92 Mil.
Property, Plant and Equipment(Net PPE) was $37.51 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.52 Mil.
Selling, General, & Admin. Expense(SGA) was $51.35 Mil.
Total Current Liabilities was $99.98 Mil.
Long-Term Debt & Capital Lease Obligation was $27.17 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 53.61) / (7 / 85.488)
=0 / 0.081883
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(85.488 / 85.488) / (53.61 / 53.61)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (324.515 + 30.047) / 358.504) / (1 - (158.572 + 37.508) / 199.918)
=0.010996 / 0.019198
=0.5728

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=53.61 / 85.488
=0.6271

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.519 / (9.519 + 37.508)) / (8.689 / (8.689 + 30.047))
=0.202416 / 0.224313
=0.9024

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(56.551 / 53.61) / (51.352 / 85.488)
=1.054859 / 0.600692
=1.7561

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((19.772 + 170.728) / 358.504) / ((27.17 + 99.98) / 199.918)
=0.531375 / 0.636011
=0.8355

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-142.517 - 9.535 - -140.617) / 358.504
=-0.031896

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

WAVE Life Sciences has a M-score of -4.14 suggests that the company is unlikely to be a manipulator.


WAVE Life Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Executives
Paul Bolno director, officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Kyle Moran officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Chandra Vargeese officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Michael A. Panzara officer: Franchise Lead, Neurology 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero officer: Interim CFO 733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan director